Tuesday, 3rd of April 2012 |
‘A total of 587 vaccine and 763 placebo recipients underwent cervical surgery. The incidence of any subsequent HPV related disease was 6.6 and 12.2 in vaccine and placebo recipients respectively. . .’
Full text is at http://www.bmj.com/content/344/bmj.e1401
Abstract
Objectives To determine the effect of human papillomavirus (HPV) quadrivalent vaccine on the risk of developing subsequent disease after an excisional procedure for cervical intraepithelial neoplasia or diagnosis of genital warts, vulvar intraepithelial neoplasia, or vaginal intraepithelial neoplasia.
Design Retrospective analysis of data from two international, double blind, placebo controlled, randomised efficacy trials of quadrivalent HPV vaccine (protocol 013 (FUTURE I) and protocol 015 (FUTURE II)).
Setting Primary care centres and university or hospital associated health centres in 24 countries and territories around the world.
Participants Among 17 622 women aged 15–26 years who underwent 1:1 randomisation to vaccine or placebo, 2054 received cervical surgery or were diagnosed with genital warts, vulvar intraepithelial neoplasia, or vaginal intraepithelial neoplasia.
Intervention Three doses of quadrivalent HPV vaccine or placebo at day 1, month 2, and month 6.
Main outcome measures Incidence of HPV related disease from 60 days after treatment or diagnosis, expressed as the number of women with an end point per 100 person years at risk.
Results A total of 587 vaccine and 763 placebo recipients underwent cervical surgery. The incidence of any subsequent HPV related disease was 6.6 and 12.2 in vaccine and placebo recipients respectively (46.2% reduction (95% confidence interval 22.5% to 63.2%) with vaccination). Vaccination was associated with a significant reduction in risk of any subsequent high grade disease of the cervix by 64.9% (20.1% to 86.3%). A total of 229 vaccine recipients and 475 placebo recipients were diagnosed with genital warts, vulvar intraepithelial neoplasia, or vaginal intraepithelial neoplasia, and the incidence of any subsequent HPV related disease was 20.1 and 31.0 in vaccine and placebo recipients respectively (35.2% reduction (13.8% to 51.8%)).
Conclusions Previous vaccination with quadrivalent HPV vaccine among women who had surgical treatment for HPV related disease significantly reduced the incidence of subsequent HPV related disease, including high grade disease.
Elmar A Joura, associate professor1, Suzanne M Garland, director, professor2,
Jorma Paavonen, professor, physician in chief3, Daron G Ferris, professor4,
Gonzalo Perez, professor5, Kevin A Ault, associate professor6, Warner K Huh, associate professor7,
Heather L Sings, director of Global Scientific and Medical Publications8,
Margaret K. James, senior biometrician8, Richard M Haupt, executive director of clinical research8
for the FUTURE I and II Study Group
Author Affiliations
1Department of Gynaecology and Obstetrics, Medical University of Vienna, Comprehensive Cancer Center, Währinger Gürtel 18-20, A-1090 Vienna, Austria
2Microbiology and Infectious Diseases Department, Royal Women’s Hospital and Department of Obstetrics and Gynaecology, University of Melbourne, Murdoch Childrens Research Institute, Melbourne, Victoria, Australia
3Department of Obstetrics and Gynecology, University Central Hospital, Helsinki, Finland
4Departments of Family Medicine and Obstetrics and Gynecology, Medical College of Georgia, Augusta, GA, USA
5Universidad del Rosario, Bogotá, Colombia (now at Merck Sharp & Dohme, Whitehouse Station)
6Department of Gynecology and Obstetrics and the Emory Vaccine Center, Emory University School of Medicine and Department of Global Health, Rollins School of Public Health, Emory University Atlanta GA, USA
7Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, AL, USA
8Merck Sharp & Dohme, Whitehouse Station, NJ, USA
Correspondence to: E A Joura elmar.joura@meduniwien.ac.at
Accepted 13 January 2012
Are three drugs for malaria better than two?
Friday, 24th of April 2020 |
Public health Interventions and epidemic intensity during the 1918 influenza pandemic
Thursday, 16th of April 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
Tuesday, 17th of March 2020 |
Using models to shape measles control and elimination strategies in low- and middle-income countries: A review of recent applications
Monday, 17th of February 2020 |
Immunization Agenda 2030
Tuesday, 11th of February 2020 |
41028736 |
www.measlesinitiative.org www.technet21.org www.polioeradication.org www.globalhealthlearning.org www.who.int/bulletin allianceformalariaprevention.com www.malariaworld.org http://www.panafrican-med-journal.com/ |